Elsevier announced today that Scopus(R), its flagship product and world's largest abstract and citation (A&C) database, was selected as the sole citation provider by the Australian Research Council (ARC) for its Excellence in Research for Australia (ERA) initiative.

The ERA initiative has been designed to assess the research quality of Australia's higher education providers using a combination of indicators and expert review by committees comprised of experienced, internationally recognized experts.

"The development and growth of a world class system to evaluate research quality has always been our primary objective and Scopus was selected from a competitive tender process," said Professor Margaret Sheil, Chief Executive Officer, ARC. "The ARC welcomes this partnership with Elsevier and I thank them for the strong commitment they have shown to ERA throughout the 2009 trial, and through their tender for the position of citation provider."

The ARC has negotiated terms with Elsevier to assist Australian Universities with improving their institutional data quality using Scopus Custom Data. This collaboration also highlights the use of Scopus Custom Data for the entire process of measuring research quality.

"By harnessing the broad and rich content available in Scopus, we believe this will set the stage for a next era in research quality measurement and place ARC as one of the premier thought leaders in evaluating research quality," commented Herman Van Campenhout, CEO Science & Technology for Elsevier. "We're extremely proud to have Scopus chosen for this initiative and we're looking forward to continue and grow our relationship with the Australian Research Council."

The ARC is one of many agencies around the world that are now using Scopus data as the authoritative data source for research performance measurement including: the OECD, and more recently the Institute for Research Information and Quality Assurance (iFQ) in Germany.

Notes for Editors:

For more information on the ERA initiative, please visit:

http://www.arc.gov.au/era/default.htm

For a general overview of Scopus, please visit:

http://www.info.scopus.com/overview/

About the Australian Research Council (ARC)

The Australian Research Council (ARC) is a statutory authority within the Australian Government's Innovation, Industry, Science and Research portfolio. The ARC advises the Australian Government on research matters and manages the National Competitive Grants Program, a significant component of Australia's investment in research and development. Through the Excellence in Research for Australia (ERA) initiative the ARC will assess research quality within Australia's higher education institutions using a combination of indicators and expert review by committees comprising experienced, internationally-recognised experts.

About Scopus

Covering the world's research literature, Scopus is the largest abstract and citation database of peer-reviewed literature and quality Web sources with smart tools to track analyze and visualize research. Scopus was designed and developed with over 500 users and librarians internationally. Its unique database contains abstracts and references from nearly 18,000 titles from more than 5,000 international publishers, ensuring broad interdisciplinary coverage. In addition, Scopus not only offers users citation information about the articles covered, but also directly integrates Web and patent searches. Direct links to full-text articles, library resources and other applications like reference management software, make Scopus quicker, easier and more comprehensive to use than any other literature research tool. For more information about Scopus please visit http://www.info.scopus.com.

In October 2008, the Organization for Economic Co-Operation and Development (OECD) announced it would use Scopus Custom Data for its research, analysis and benchmarking work due to its broad international coverage, clean flexible data and advanced features. Australian Research Council (ARC) selected Scopus to provide citation information for the Excellence in Research for Australia (ERA) initiative Cluster One evaluation. And of the top fifty universities, as ranked by Time Higher Education (THE) World University Rankings, 50% of them depend on Scopus and the percentage increases each year.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact: Anne Harvey
    Direct: +61-294-228-564
    E-mail: a.harvey@elsevier.com

Contact: Anne Harvey, Direct: +61-294-228-564, E-mail: a.harvey@elsevier.com

"We are extremely grateful to Elsevier for choosing to contribute MD Consult subscriptions and financial support to MSF," said Jennifer Tierney, Director of Development, MSF-USA. "Its generosity will help to provide essential emergency medical care to people caught in medical crisis at what could be the most vulnerable moment of their lives. Whether treating children for acute malnutrition, vaccinating against diseases like meningitis or providing aid to people suffering from a natural disaster, Elsevier's contribution will make a substantial difference to our programs around the world."

Both Elsevier and MSF share a commitment to advancing global healthcare through timely, accurate clinical knowledge and data. MSF aid workers operate programs in more than 60 countries, from Cambodia, Guatemala and Armenia, to Burundi, Brazil and Bosnia. Elsevier, in turn, has 7,000 employees working in more than 70 offices worldwide and a track record of partnership with global science and health communities in Asia, Africa, Europe, North and South America, the Middle East and the U.S. Clinicians in more than 139 countries throughout the world now use Elsevier's CDS tools.

"During this season of giving and compassion, Elsevier wanted to donate CDS tools that will surely enhance care and improve outcomes for patients living in troubled spots of the world," said Randy Charles, Managing Director, Global Clinical Reference, Elsevier. "By supporting MSF physicians through 'All You Need to Make a Difference,' Elsevier fulfills its global healthcare mission of building insight and breaking boundaries. Elsevier is dedicated to providing every clinician in the world with accurate, evidence-based, interactive answers to the most critical clinical questions."

MD Consult will also help volunteer physicians diagnose and treat conditions associated with armed conflict, malnutrition, natural disasters and lack of access to care, and other epidemics. With a world population of close to seven billion people, some 32.9 million have HIV/AIDS, 13,700,000 have tuberculosis and 247,000,000 have malaria, according to the Kaiser Family Foundation's Global Health Facts.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Doctors Without Borders/Medecins Sans Frontieres (MSF):

Doctors Without Borders/Medecins Sans Frontieres (MSF) is an international medical humanitarian organization created by doctors and journalists in France in 1971. Today, MSF provides aid in more than 60 countries to people whose survival is threatened by violence, neglect, or catastrophe, primarily due to armed conflict, epidemics, malnutrition, exclusion from health care or natural disasters. MSF provides independent, impartial assistance to those most in need. MSF reserves the right to speak out to bring attention to neglected crises, to challenge inadequacies or abuse of the aid system, and to advocate for improved medical treatments and protocols. In 1999, MSF was awarded the Nobel Peace Prize in recognition of its work. For more information visit www.doctorswithoutborders.org.

    Contact:  Tom Reller
              Vice President of Global Relations, Elsevier
              212.462.1912
              T.Reller@Elsevier.com

SOURCE Elsevier

http://www.elsevier.com

Mylan SA ranks third in Spain's generics market with nearly 200 products. Based in Barcelona, the company also runs a logistics centre in Llica d'Amunt, from where it offers superior service to pharmacies, distributors and hospitals across the country.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

http://www.mylan.com

7.00am GMT 11 November 2009

Erik Engstrom appointed as Chief Executive Officer of Reed Elsevier

Reed Elsevier announces that Ian Smith has resigned as Chief Executive Officer by mutual agreement and has with effect from today stepped down from the Boards.

Erik Engstrom, currently CEO of Elsevier, has been appointed Chief Executive Officer of Reed Elsevier with immediate effect.

Anthony Habgood, Chairman, said:

"Ian has had the difficult task of leading Reed Elsevier during unprecedentedly turbulent economic times. The Boards and I would like to thank him for his contribution in this respect and wish him well for the future.

"Erik is a proven international executive with over 15 years management experience in the media sector in the US and Europe including five highly successful years developing our worldwide Elsevier business as its CEO. He is now well suited to lead Reed Elsevier, to create value for our shareholders and to deliver growth as economic conditions improve."

Erik Engstrom said:

"I am delighted to be leading Reed Elsevier. The business is strongly positioned in attractive markets and I am confident that we have the resources and ambition to be highly competitive. We have talented people across Reed Elsevier who are passionate about what they do and about serving our professional customers."

- ENDS 	- Enquiries

Patrick Kerr (Media)

+44 20 7166 5646

Sybella Stanley (Investors)

+44 20 7166 5630

Notes to Editors

About Reed Elsevier

Reed Elsevier is a world leading publisher and information provider targeting the science and medical, legal and risk management, and business to business sectors. We provide high value and flexible information solutions to professional users, with increasing emphasis on internet delivery.

Reed Elsevier employs 33,000 people, including approximately 18,000 in North America.

In February 2009, Reed Elsevier reported revenues for 2008 of GBP5,334/E6,721m.

Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

About Erik Engstrom

Mr Engstrom (46) has been a director of Reed Elsevier Group plc and Reed Elsevier PLC since 2004 and a Member of the Executive Board of Reed Elsevier NV since 2005.

Mr Engstrom has been CEO of Elsevier since joining Reed Elsevier in 2004 and under his stewardship sales and profits have grown every year creating a business with turnover of GBP1.7 billion in 2008.

Prior to joining Reed Elsevier, Mr Engstrom worked from 2001 to 2004 at General Atlantic Partners, a private equity firm, where he was a general partner leading their media and consumer investment sector. Prior to that, Mr Engstrom had extensive experience in the publishing sector from 1991 to 2001 as president and chief operating officer of Random House Inc. and, before its merger with Random House, as president and chief executive officer of Bantam Doubleday Dell North America. Mr Engstrom, a native of Sweden, began his business career as a consultant with McKinsey after gaining his MBA from Harvard Business School where he was a Fulbright Scholar.

Mr Engstrom has also been a director of a number of publicly quoted companies, including SCA, a Swedish-based paper products company with revenues of E12 billion in 2008.

Mr Engstrom will be paid an annual salary of GBP1,000,000 and will participate in Reed Elsevier's established bonus and long-term incentive schemes which would deliver an additional 3.5x salary at target.

Copyright Hugin

This announcement is originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

[CN#160323]